Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
936 Total results for product and free and sample content found
Citeline
By Loni Branon 25 May 2018
The 9th Annual SCOPE (Summit for Clinical Trials Operations Executives) Summit has concluded: join industry expert and clinical trial planning thought leader Loni Branon as she hosts a follow-up to this important annual event, where Informa Pharma Intelligence hosted a launch party for our exciting new Citeline platform
Topic Clinical trials
Scrip
By Ian Haydock 25 May 2018
Chugai's new CEO Tatsuro Kosaka took up his position in March and is charged with taking the major Japanese company through the next stage of development as key products reach the global market and others begin to face biosimilar competition. In this first part of a two-part exclusive interview, he outlines the firm's vision, approach to R&D and how the strategic alliance with Roche is playing out.
Topic Business strategies Research
Scrip
By Jessica Merrill 25 May 2018
The price of new oncology brands doubled in the US from 2013 to 2017, bringing the median annual price to more than $160,000 last year, up from $79,000 in 2013, according to a new IQVIA report. Spending on cancer drugs in the US has doubled since 2012, reaching nearly $50bn in 2017.
Topic Cancer
Citeline
By Loni Branon 24 May 2018
The 9th Annual SCOPE (Summit for Clinical Trials Operations Executives) Summit has concluded: join industry expert and clinical trial planning thought leader Loni Branon as she hosts a follow-up to this important annual event, where Informa Pharma Intelligence hosted a launch party for our exciting new Citeline platform.
Topic Clinical trials
Medtech Insight
By Derrick Gingery 24 May 2018
Companion diagnostics are poised to be a huge growth area worldwide, with a CAGR of 20.1% over the next 5 years, making it a $6B industry by 2022. These often in-vitro medical devices provide essential information for the efficacy of a corresponding drug or biological product, and are also used for pre-determining the efficacy of treatment. Their growth is being propelled in most countries by a number of favorable factors.
Topic Medtech
Pharmaprojects
By Ian Lloyd 24 May 2018
Keep in tune with the current landscape for pharma R&D with a free, information-packed webinar recording from Informa Pharma Intelligence. In the Global Pharma R&D Review webinar, our experts hit all the right notes as they used a music theme to explore key issues affecting R&D today, and offer a glimpse of what the rest of 2018 may look like.
Scrip
By Brenda Sandburg 23 May 2018
Xtandi use in early prostate cancer, lorlatinib as second-line treatment for non-small cell lung cancer and dacomitinib for first-line NSCLC have upcoming user fee dates.
Topic Cancer
Scrip
By Brian Yang 23 May 2018
As the Congo grapples with the latest outbreak of Ebola, China has approved its first domestically developed vaccine in record time, hailing it a national innovation champion. But as the World Health Organization starts vaccinations in Africa, can China make the cut and compete with global players including Merck & Co?
Topic Vaccines
Medtech Insight
22 May 2018
While only two devices have received approval and a national coverage determination through US FDA/CMS' parallel review program, a top CMS official says industry needs to look beyond just the numbers. Instead, she says the parallel review program is part of a sea-change that has allowed for better communication between CMS, FDA and sponsors.
Topic FDA
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Report store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
